首页> 美国卫生研究院文献>Journal of Clinical Oncology >Health-Related Quality-of-Life Results From the Open-Label Randomized Phase III ASPIRE Trial Evaluating Carfilzomib Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

【2h】

Health-Related Quality-of-Life Results From the Open-Label Randomized Phase III ASPIRE Trial Evaluating Carfilzomib Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

机译：评估卡非佐米来那度胺和地塞米松与来那度胺和地塞米松在复发性多发性骨髓瘤患者中的开放标签随机III期ASPIRE试验与健康相关的生活质量结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo determine the effects of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) on health-related quality of life (HR-QoL) in the Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone for the Treatment of Patients With Relapsed Multiple Myeloma (ASPIRE) trial.

机译：目的确定卡非佐米，来那度胺和地塞米松（KRd）与来那度胺和地塞米松（Rd）对卡非佐米，来那度胺和地塞米松与来那度胺和地塞米松患者的健康相关生活质量（HR-QoL）的影响具有复发性多发性骨髓瘤（ASPIRE）试验。

著录项

期刊名称 Journal of Clinical Oncology
作者
A. Keith Stewart; Meletios A. Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S. Siegel; Ruben Niesvizky; Andrzej J. Jakubowiak; Jesus F. San-Miguel; Heinz Ludwig; Jacqui Buchanan; Kim Cocks; Xinqun Yang; Biao Xing; Naseem Zojwalla; Margaret Tonda; Philippe Moreau; Antonio Palumbo;
展开▼
作者单位

展开▼
年(卷),期 -1(34),32
年度 -1
页码 3921–3930
总页数 14
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma [J] . Stewart A. Keith, Dimopoulos Meletios A., Masszi Tamas, Journal of Clinical Oncology . 2016,第32期

机译：评估卡非佐米，来那度胺和地塞米松与来那度胺和地塞米松在复发性多发性骨髓瘤患者中的开放标签，随机，III期ASPIRE试验与健康相关的生活质量结果
2. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma [J] . Marc-Andrea Baertsch, Jana Schlenzka, Elias K. Mai, BMC Cancer . 2016,第1期

机译：德语德语骨髓瘤多中心小组（GMMG）试验ReLApsE的原理和设计：来那度胺/地塞米松与来那度胺/地塞米松联合随后自体干细胞移植和来那度胺维持治疗多发性骨髓瘤患者的随机，开放，多中心III期试验
3. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation: Secondary Analysis from the Phase 3 Aspire Study (NCT01080391) [J] . Hari Parameswaran N., Song Kevin, Bensinger William, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第3Suppla1期

机译：卡非佐米，来那度胺和地塞米松与来那度胺和地塞米松对自体干细胞移植后复发性多发性骨髓瘤患者的疗效和安全性：3期Aspire研究的二级分析（NCT01080391）
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study [O] . Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, 2018

机译：在III期ASPIRE研究中使用卡非佐米来那度胺和地塞米松（KRd）与来那度胺和地塞米松（Rd）治疗的复发性多发性骨髓瘤患者根据计划的治疗持续时间无应答和无进展生存
7. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study [O] . Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, 2018

机译：根据患有用Carfilzomib，Lenalymide和Dexamethasone（KRD）的多发性骨髓瘤患者的计划治疗持续时间的反应和无进展生存期与III期Aspire Chinain的Lenalalomide（KRD）与番醇胺和地塞米松（RD）进行了近期骨髓瘤

Health-Related Quality-of-Life Results From the Open-Label Randomized Phase III ASPIRE Trial Evaluating Carfilzomib Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

摘要

著录项

相似文献

相关主题

期刊订阅